

FINANCIAL STATEMENTS (Unaudited)
For the period from 01.07.2025 to 31.03.2026





THE IBN SINA PHARMACEUTICAL INDUSTRY PLC


Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)
As at 31 March 2026

		Amount in Taka	
	Notes	31 March 2026	30 June 2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04.A	6,739,920,381 2,581,553,850	4,701,323,681 2,655,519,636
Capital Work-In-Progress	05.A	4,085,151,185	1,932,358,746
Right-of-Use Assets	05.B	14,469,311	33,072,711
Advances, Deposits & Prepayments	10.A.1	17,572,000	33,715,070
Financial Assets	06.A	41,174,034	46,657,518
		3,201,872,513	2,845,250,397
Current Assets :			
Financial Assets	7.B	42,658,337	22,500,000
Inventories	08.A	1,878,144,086	1,808,087,123
Trade and Other Receivables	09.A	289,090,642	196,052,607
Advances, Deposits & Prepayments	10.A	656,909,771	503,707,520
Cash & Cash Equivalents	11.A	335,069,678	314,903,147
TOTAL ASSETS		9,941,792,894	7,546,574,078
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Equity attributable to the owners of the company:			
Share Capital	12	4,346,141,823 312,436,270	3,926,901,664 312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,479,467)	(15,544,331)
Retained Earnings	15.A	4,049,792,910	3,625,617,615
Non Controlling Interests	15.B	104,810,340	70,946,596
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16.A	1,393,231,393 1,285,995,267	1,072,158,461 974,705,376
Employee Benefit Obligations	17.A	2,340,118	990,546
Deferred Tax Liabilities	19	104,896,008	96,462,538
Current Liabilities:			
Short Term Finance	20.A	4,097,609,338 2,194,647,082	2,476,567,357 953,683,239
Current Portion of Long Term Finance	21	89,584,391	119,445,855
Lease Liabilities	17.B	2,593,504	23,798,698
Trade and Other Payable	22.A	1,089,806,707	842,289,126
Unclaimed Dividend	22.B	33,492,555	42,104,508
Income Tax Payables	23.A	687,485,099	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		9,941,792,894	7,546,574,078
Net Assets Value (NAV) Per Share	31.A	139.10	125.69


Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director



Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)


For the period from 1 July 2025 to 31 March 2026

Amount in Taka

	Notes	1 July 2025 to 31 March 2026	1 July 2024 to 31 March 2025	1 January 2026 to 31 March 2026	1 January 2025 to 31 March 2025
REVENUE	24.A	10,405,244,535	8,813,387,803	2,940,074,783	2,883,341,512
Cost of goods sold	24.C	(6,158,854,526)	(5,280,430,823)	(1,744,944,246)	(1,746,401,994)
GROSS PROFIT		4,246,390,009	3,532,956,979	1,195,130,537	1,136,939,517
OPERATING EXPENSES		(3,314,548,006)	(2,808,179,990)	(951,109,489)	(877,273,371)
Administrative expenses	25.A	(230,136,793)	(205,598,166)	(94,762,606)	(71,483,147)
Selling and Distribution expenses	26.A	(3,084,411,213)	(2,602,581,825)	(856,346,883)	(805,790,225)
OPERATING PROFIT		931,842,003	724,776,989	244,021,048	259,666,146
Finance charges	34.A	(90,189,097)	(59,673,370)	(38,736,518)	(20,919,747)
Other income		24,101,284	16,129,017	5,789,861	4,400,369
Profit before WPPF and welfare fund		865,754,189	681,232,637	211,074,390	243,146,769
Workers' P.P. fund and welfare fund	27.A	(42,631,648)	(34,635,324)	(10,501,767)	(9,344,517)
PROFIT BEFORE TAX		823,122,541	646,597,313	200,572,623	233,802,252
Income tax expenses	28.A	(200,124,289)	(177,230,718)	(54,805,488)	(60,302,842)
PROFIT FOR THE PERIOD		622,998,252	469,366,595	145,767,135	173,499,410
PROFIT/(LOSS) ATTRIBUTABLE TO:					
Owners of the Company		624,134,508	468,979,451	146,219,979	173,571,500
Non-controlling interest		(1,136,256)	387,144	(1,819,668)	(72,090)
		622,998,252	469,366,595	144,400,311	173,499,410
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(5,483,484)	(3,735,311)	471,605	(678,849)
Less: Deferred tax		(548,348)	(373,531)	47,160	(67,885)
Total other comprehensive income for the period, net of tax		(4,935,136)	(3,361,780)	424,444	(610,964)
Total Comprehensive Income for the period		618,063,117	466,004,815	146,191,580	172,888,446
Total Comprehensive income Attributable to:					
Owner of the Company		619,199,372	465,617,671	146,644,423	172,960,536
Non-controlling interest		(1,136,256)	387,144	(1,819,668)	(72,090)
		618,063,117	466,004,815	144,824,756	172,888,446
Earnings Per Share (EPS)	30.A	19.94	15.02	4.67	5.55
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the period from 1 July 2025 to 31 March 2026

Amount in Taka


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2025			(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the year 30 June 2024 (Cash-60%)				(196,834,850)		(196,834,850)
Issued during the year					35,000,000	35,000,000
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,625,617,615	70,946,596	3,997,848,260
Statement of profit or loss and other Comprehensive Income for period ended 31 March, 2026			(4,935,136)	624,134,508	(1,136,256)	618,063,117
Dividend for the year 30 June, 2025 (Cash-64%)				(199,959,213)		(199,959,213)
Issued during the year					35,000,000	35,000,000
Balance as at 31 March 2026	312,436,270	4,392,110	(20,479,468)	4,049,792,910	104,810,340	4,450,952,163


CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the period from 1 July 2024 to 31 March 2025

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,367	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	670,522,122	828,351	665,006,104
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)		(187,461,762)
Issue during the year						
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2025			(3,361,780)	468,979,451	387,144	466,004,815
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Issue during the year					35,000,000	35,000,000
Balance as at 31 March 2025	312,436,270	4,392,110	(11,972,501)	3,461,407,715	71,266,862	3,837,530,457


Chief Financial Officer


Company Secretary


Director, Finance


Dated, Dhaka
22 April 2026



Managing Director



Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)
For the period from 1 July 2025 to 31 March 2026

	Amount in Taka	
	01 July 2025 to 31 March 2026	01 July 2024 to 31 March 2025
Cash Flows From Operating Activities:		
Received from revenue and others	10,312,206,500	8,801,401,455
Payment for operation, expenses & others	(9,180,179,837)	(7,807,221,620)
Miscellaneous income	614,526	939,011
Cash generated from operations	1,132,641,189	995,118,846
Income tax paid	(121,195,198)	(121,071,080)
Payment for Financial charges	(89,008,419)	(56,685,494)
Net cash provided by operating activities	922,437,572	817,362,271
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(2,225,597,002)	(653,186,915)
Acquisition of financial assets	(14,674,853)	70,544,340
Received from bank	1,957,788	5,430,918
Net cash used in investing activities	(2,238,314,066)	(577,211,657)
Cash Flows From Financing Activities:		
Payment of dividend	(208,571,167)	(178,147,838)
Payment of lease liabilities	(22,385,873)	(22,038,783)
Received from Non Controlling Interests	35,000,000	10,000,000
Long term finance received/(paid) from bank (Net)	311,289,891	390,818,350
Short term finance received/(paid) from bank (Net)	1,211,102,379	(413,267,038)
Net cash used in financing activities	1,326,435,231	(212,635,308)
Increase/(decrease) in cash and cash equivalents	10,558,737	27,515,306
Cash and cash equivalents at 1 July	314,903,147	365,229,893
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	9,607,793	1,039,444
Cash and cash equivalents at 31 March	335,069,678	393,784,643
NOCFPS (Note 32.A)	29.52	26.16



Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31 March 2026

Amount in Taka

	Notes	31 March 2026	30 June 2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04	2,335,558,134	2,431,653,536
Capital Work-In-Progress	05	3,134,371,757	1,155,822,174
Right-of-Use Assets	05.B	14,469,311	33,072,711
Financial Assets	06	12,174,034	17,657,518
Advances, Deposits & Prepayments	10.1.A	17,322,000	33,715,070
Investment in Subsidiaries	07	1,183,169,470	1,038,169,470
		6,697,064,706	4,710,090,480
Current Assets :			
Financial Assets	07.A	42,658,337	22,500,000
Inventories	08	1,665,107,965	1,603,775,310
Trade and Other Receivables	09	259,459,790	187,596,187
Advances, Deposits & Prepayments	10.1	595,829,800	429,600,396
Cash & Cash Equivalents	11	193,422,679	180,681,788
		2,756,478,571	2,424,153,681
TOTAL ASSETS		9,453,543,277	7,134,244,160
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,479,467)	(15,544,331)
Retained Earnings	15	4,047,734,323	3,631,099,007
		4,344,083,237	3,932,383,056
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16	1,063,704,824	753,223,072
Employee Benefit Obligations	17	2,340,118	990,546
Deferred Tax Liabilities	18	103,114,510	94,711,750
		1,169,159,452	848,925,369
Current Liabilities:			
Short Term Finance	20	2,179,830,186	933,771,898
Current Portion of Long Term Finance	21	89,584,391	119,445,855
Lease Liabilities	17.B	2,593,504	23,798,698
Trade and Other Payables	22	998,990,781	775,229,847
Unclaimed Dividend	22.B	33,492,555	42,104,508
Income Tax Payables	23	635,809,171	458,584,929
		3,940,300,587	2,352,935,735
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		9,453,543,277	7,134,244,160
Net Assets Value (NAV) Per Share	31	139.04	125.86



Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)


For the period from 1 July 2025 to 31 March 2026

Amount in Taka

Notes	1 July 2025 to 31 March 2026	1 July 2024 to 31 March 2025	1 January 2026 to 31 March 2026	1 January 2025 to 31 March 2025
REVENUE				
24	9,275,780,294	7,995,902,307	2,619,460,891	2,585,983,653
24.B	(5,525,696,975)	(4,793,671,477)	(1,564,305,921)	(1,569,924,874)
GROSS PROFIT	3,750,083,319	3,202,230,829	1,055,154,970	1,016,058,778
OPERATING EXPENSES				
25	(2,841,949,885)	(2,427,697,936)	(811,740,388)	(775,770,514)
Administrative expenses	(182,145,173)	(174,102,198)	(79,784,527)	(61,453,447)
26	(2,659,804,712)	(2,253,595,738)	(731,955,861)	(714,317,067)
Selling & Distribution expenses				
OPERATING PROFIT	908,133,434	774,532,893	243,414,582	240,288,264
34	(90,189,097)	(59,673,370)	(38,736,518)	(20,919,747)
Finance charges	23,812,505	12,482,276	5,778,082	4,116,175
Other income	841,756,842	727,341,800	210,456,146	223,484,693
Profit before WPPF and welfare fund				
27	(40,083,659)	(34,635,324)	(10,021,721)	(10,642,128)
Workers' P.P. fund and welfare fund				
PROFIT BEFORE TAX	801,673,183	692,706,476	200,434,425	212,842,565
28	(185,078,653)	(171,134,388)	(52,068,961)	(58,197,975)
Income tax expenses				
PROFIT FOR THE PERIOD	616,594,530	521,572,088	148,365,464	154,644,590
Other Comprehensive Income:				
29	(5,483,484)	(3,735,311)	471,605	(678,849)
Change in fair value of Marketable Securities	(548,348)	(373,531)	47,160	(67,885)
Less: Deferred tax	(4,935,136)	(3,361,780)	424,444	(610,964)
Total other comprehensive income for the period, net of tax	611,659,394	518,210,308	148,789,908	154,033,626
Total Comprehensive Income for the period				
30	19.74	16.69	4.76	4.93
Earnings Per Share (EPS)				
Number of Shares used to Compute EPS	31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the period from 1 July 2025 to 31 March 2026


Particulars	Amount in Taka				
	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,492
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2025			(6,933,611)	660,162,024	653,228,413
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,631,099,006	3,932,383,056
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2026			(4,935,136)	616,594,530	611,659,394
Dividend for the year 30 June, 2025 (Cash-64%)				(199,959,213)	(199,959,213)
Balance as at 31 March 2026	312,436,270	4,392,110	(20,479,468)	4,047,734,323	4,344,083,237

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the period from 1 July 2024 to 31 March 2025

Particulars	Amount in Taka				
	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	655,067,965	648,723,597
Dividend for the period 30 June 2023 (Cash - 60%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,832	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 31 March 2025			(3,361,780)	521,572,088	518,210,308
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 31 March 2025	312,436,270	4,392,110	(11,972,500)	3,492,509,070	3,797,364,950



Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS (Unaudited)
For the period from 1 July 2025 to 31 March 2026

	Amount in Taka	
	01 July 2025 to 31 March 2026	01 July 2024 to 31 March 2025
Cash Flows From Operating Activities:		
Received from revenue and others	9,203,916,691	7,963,357,273
Payment for operation, expenses & others	(8,102,003,283)	(7,087,146,682)
Miscellaneous income	614,526	939,011
Cash generated from operations	1,102,527,934	877,149,602
Cash generated from discontinued operation		
Income tax paid	(113,899,225)	(115,444,950)
Payment for Financial charges	(89,008,419)	(56,685,494)
Net cash provided by operating activities	899,620,290	705,019,158
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(2,034,202,886)	(565,027,964)
Investment in Subsidiary	(145,000,000)	(70,000,000)
Acquisition of financial assets	(14,674,853)	70,544,340
Received from bank	1,669,009	400,400
Net cash used in investing activities	(2,192,208,730)	(564,083,224)
Cash Flows From Financing Activities:		
Payment of dividend	(208,571,167)	(178,147,838)
Payment of lease liabilities	(22,385,873)	(21,768,783)
Long term finance received/(paid) from bank (Net)	310,481,752	288,325,822
Short term finance received/(paid) from bank (Net)	1,216,196,824	(310,883,595)
Net cash used in financing activities	1,295,721,537	(222,474,393)
Increase/(decrease) in cash and cash equivalents	3,133,098	(81,538,459)
Cash and cash equivalents at 1 July	180,681,788	312,475,845
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	9,607,793	1,039,444
Cash and cash equivalents at 31 March	193,422,679	231,976,830
NOCFPS (Note 32)	28.79	22.57



Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
22 April 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)
For the period from 1 July 2025 to 31 March 2026

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange PLC (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2025.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 22 April 2026 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2025.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 31 March 2026 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2025 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in sales revenue and profit , EPS has been increased during current period over last reporting period.

3.4 INCREASE IN COST OF METRIALS:

Cost of metrials increase due to increase in dollar rate against Bangladesh Taka.

3.5 INCOME TAX:

Payment of income tax increased due to increase in revenue and net profit. Advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

3.7 Other income increased during the period due to increase in revenue from toll production charge and increased in foreign exchange fluctuation gain on FCAD ERQ Accounts .

3.8 Payment of dividend increased due to amount paid share holders during the reporting period.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets and payment of share capital of The IBN SINA API Industry Ltd. than the same period of last year.

3.12 SHORT TERM FINANCE:

Short term finance increased during the period due to purchases of machinery and materials.

3.13 INCREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share(NOCFPS) increased during current period over last reporting period due to decrease in payment for cost & expenses & others.

3.14 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

	31 March 2026	30 June 2025
04. PROPERTY, PLANT AND EQUIPMENT:		
Cost :		
Opening balance	4,169,069,419	3,956,915,644
Addition during the period	36,779,874	215,232,652
Disposal/Adjustment during the period	-	(3,078,877)
Closing balance	4,205,849,293	4,169,069,419
Accumulated Depreciation:		
Opening balance	1,737,415,882	1,554,782,910
Charged during the period	132,875,278	185,554,095
Disposal/Adjustment during the period	-	(2,921,123)
Closing balance	1,870,291,160	1,737,415,883
Closing balance of Written Down Value (WDV)	2,335,558,134	2,431,653,536

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry PLC	2,335,558,134	2,431,653,536
The IBN SINA API Industry Ltd.	166,409,658	142,245,156
The IBN SINA Polymer Industry Ltd.	2,456,184	2,288,106
The IBN SINA Natural Medicine Ltd.	77,129,874	79,332,838
	2,581,553,850	2,655,519,636

05. CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)

Opening balance	711,323,283	366,379,612
Addition during the period	150,989,782	344,943,671
Less: Transferred to property plant and equipment	-	-
Closing balance	862,313,065	711,323,283

B) Machinery in transit and installation

Opening balance	398,469,652	213,664,954
Addition during the period	1,846,433,230	310,149,835
Less: Transferred to property, plant and equipment	-	(125,345,137)
Closing balance	2,244,902,882	398,469,652
Other Goods-In-Transit	27,155,810	46,029,239
	3,134,371,757	1,155,822,174

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

ii) Building construction in the factory premises has been completed during this period and hence the construction and associated cost is transferred from capital work in progress to building under property, plant and equipment.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)

Opening balance	939,492,119	465,469,776
Addition during the period	266,411,148	474,022,343
Less: Transferred to property plant and equipment	-	-
Closing balance	1,205,903,267	939,492,119

B) Machinery in transit and installation

Opening balance	946,837,388	673,427,435
Addition during the period	1,905,254,721	398,755,090
Less: Transferred to property, plant and equipment	-	(125,345,137)
Closing balance	2,852,092,109	946,837,388
Other Goods-In-Transit	27,155,810	46,029,239
	4,085,151,185	1,932,358,746

	Amount in Taka	
	31 March 2026	30 June 2025
05.B RIGHT-OF-USE ASSETS:		
Opening balance	130,252,602	130,252,602
Addition during the period	-	-
Disposal/Adjustment during the period	-	-
Closing balance	130,252,602	130,252,602
Accumulated Depreciation:		
Opening balance	97,179,891	72,375,357
Addition during the period	18,603,400	24,804,533
Disposal/Adjustment during the period	-	-
Closing balance	115,783,291	97,179,891
Closing balance of Written Down Value (WDV)	14,469,311	33,072,711

06. FINANCIAL ASSETS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,812,800	1,699,500
Al-Arafah Islami Bank PLC	1,730,400	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC in MPB	3,073,005	2,939,895
	12,174,034	17,657,518

The above investment in marketable securities are designated as Fair Value through Other Comprehensive Income (FVOCI) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank PLC and IBBP-MPB are listed in Dhaka Stock Exchange PLC and Chittagong Stock Exchange PLC. The whole investment in shares of both the companies are in DSE only.

06.A CONSOLIDATED FINANCIAL ASSETS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,812,800	1,699,500
Al-Arafah Islami Bank PLC	1,730,400	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC (IBBP) in MPB	3,073,005	2,939,895
Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
	41,174,034	46,657,518

07 INVESTMENT IN SUBSIDIARIES :		
The IBN SINA API Industry Ltd.	749,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.	195,000,000	130,000,000
	1,183,169,470	1,038,169,470

i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.8 crore have been paid as a part of share capital.

ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.

iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company. Tk. 6.5 crore has been paid as a part of share capital which has been decided in the Board meeting.

07.A FINANCIAL ASSETS (CURRENT PORTION):		
Opening Balance	22,500,000	22,500,000
Addition during the year	20,158,337	-
Investment in MTD	42,658,337	22,500,000

07.B CONSOLIDATED FINANCIAL ASSETS (CURRENT PORTION):		
Opening Balance	22,500,000	22,500,000
Addition during the year	20,158,337	-
Investment in MTD	42,658,337	22,500,000

	Amount in Taka	
	31 March 2026	30 June 2025
08. INVENTORIES:		
Raw materials	676,633,854	661,133,854
Packing materials	246,417,875	230,992,875
Work-in-process	117,991,974	97,983,312
Finished goods	371,044,770	357,701,249
Physicians' samples	5,980,277	5,836,177
Pad & literature	4,290,348	4,127,335
Spares & stores	390,344	360,234
Indirect materials	469,038	463,694
Printing & stationery	407,338	393,698
Laboratory chemicals	237,786	236,318
Material in transit	241,244,361	244,546,564
	<u>1,665,107,965</u>	<u>1,603,775,310</u>

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, mili gram, ton, liter and pcs as such quantity can not be inserted.

ii) There is no damage goods or slow moving item in the inventory list.

iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.

iv) Inventory for raw materials , packing materials, Work In Process, Finished goods and material in transit increased during the period for ensuring smooth supply of goods to meetup increased customer demand.

08.A CONSOLIDATED INVENTORIES:

Raw materials	779,186,602	768,094,729
Packing materials	270,414,882	245,848,438
Work-in-process	128,989,931	111,124,876
Finished goods	443,531,088	424,409,351
Physicians' samples	8,982,368	8,481,886
Pad & literature	4,290,348	4,127,335
Spares & stores	390,344	360,234
Indirect materials	469,038	463,694
Printing & stationery	407,338	393,698
Laboratory chemicals	237,786	236,318
Material in transit	241,244,361	244,546,564
	<u>1,878,144,086</u>	<u>1,808,087,123</u>

09. TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	256,549,597	181,402,168
Receivable from provident fund (PF)	-	304,966
Profit receivable from MTD	1,873,051	3,391,971
Other receivable-toll charge	1,037,141	2,497,081
	<u>259,459,790</u>	<u>187,596,187</u>

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.

ii) Other receivable increased during the period as all bill except last month toll charge bill have been received.

iii) Trade receivable increased during the period due to increase in sales revenue and customer types.

09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	286,180,449	189,858,588
Receivable from provident fund (PF)	-	304,966
Profit receivable from MTD	1,873,051	3,391,971
Other receivable-toll charge	1,037,141	2,497,081
	<u>289,090,642</u>	<u>196,052,607</u>

	Amount in Taka	
	31 March 2026	30 June 2025
10. ADVANCES, DEPOSITS and PREPAYMENTS :		
a. Advances against		
Salary	6,516,450	5,482,341
Expenses/works/others	12,561,614	12,433,414
Depot rent	6,971,187	6,727,985
Motor cycles-to employees	75,847,881	42,143,838
Others	745,298	706,533
	<u>102,642,430</u>	<u>67,494,111</u>
b. Income tax		
Opening balance	374,539,128	200,028,807
Addition	113,899,225	174,510,320
Adjusted during the period	-	-
	<u>488,438,352</u>	<u>374,539,128</u>
c. Deposits		
Security money	22,070,772	21,275,544
d. Pre payments		
Value Added Tax	245	6,683
	<u>613,151,800</u>	<u>463,315,466</u>
10.1 MATURITY ANALYSIS:		
Realizable/adjustable within one year.	595,829,800	429,600,396
Realizable/adjustable after one year.	17,322,000	33,715,070
	<u>613,151,800</u>	<u>463,315,466</u>
10.A CONSOLIDATED ADVANCES, DEPOSITS AND PREPAYMENTS :		
a. Advances against		
Salary	10,448,680	9,555,942
Expenses/works/others	14,296,418	31,119,648
Depot rent	6,971,187	6,727,985
Motor cycles-to employees	91,048,900	61,431,738
Others	3,246,957	2,101,636
	<u>126,012,142</u>	<u>110,936,949</u>
b. Income tax		
Opening balance	404,148,716	223,481,751
Addition	121,195,198	180,666,965
Adjusted during the period	-	-
	<u>525,343,914</u>	<u>404,148,716</u>
c. Deposits		
Security money	23,125,469	22,330,241
d. Pre payments		
Value Added Tax	245	6,683
	<u>674,481,771</u>	<u>537,422,590</u>
The company did not give any advance, deposit and prepayment to the director's of the company, subsidiaries and other connected parties and employees advances are realised in normal course of business.		
10.A.1 MATURITY ANALYSIS:		
Realizable/adjustable within one year.	656,909,771	503,707,520
Realizable/adjustable after one year.	17,572,000	33,715,070
	<u>674,481,771</u>	<u>537,422,590</u>
11. CASH AND CASH EQUIVALENTS:		
a. Cash in hand	7,243,492	6,613,494
b. Cash at bank	182,639,187	170,528,294
c. Imprest cash	3,540,000	3,540,000
	<u>193,422,679</u>	<u>180,681,788</u>

		Amount in Taka	
		31 March 2026	30 June 2025
11.A CONSOLIDATED CASH AND CASH EQUIVALENTS:			
a. Cash in hand		8,267,066	7,137,453
b. Cash at bank		323,132,612	304,095,694
c. Imprest cash		3,670,000	3,670,000
		<u>335,069,678</u>	<u>314,903,147</u>
12. SHARE CAPITAL:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each		<u>500,000,000</u>	<u>500,000,000</u>
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash		<u>312,436,270</u>	<u>312,436,270</u>
The Shareholdings consist of:			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	213	7,868,943	25.19%
General Public	12,186	9,531,372	30.51%
	<u>12,400</u>	<u>31,243,627</u>	<u>100.00%</u>
The distribution schedule showing the number of share holders and their share holdings as on 31.03.2026 are as follows:			
Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,822	1,714,246	5.49%
500 to 5,000 shares	2,215	3,357,361	10.75%
5,001 to 10,000 shares	183	1,330,481	4.26%
10,001 to 20,000 shares	91	1,219,556	3.90%
20,001 to 30,000 shares	24	555,399	1.78%
30,001 to 40,000 shares	14	496,544	1.59%
40,001 to 50,000 shares	9	416,447	1.33%
Above 50,000 shares	42	22,153,593	70.91%
	<u>12,400</u>	<u>31,243,627</u>	<u>100.00%</u>
The shares are listed with the Dhaka Stock Exchange PLC and Chittagong Stock Exchange PLC. The shares were quoted at Tk.315.80 in the Dhaka Stock Exchange PLC on 31.03.2026 and at Tk.332 in the Chittagong Stock Exchange PLC on 31.03.2026 respectively.			
13. TAX HOLIDAY RESERVE:		<u>4,392,110</u>	<u>4,392,110</u>
This represents provision made out of profit of Tax Holiday period in accordance with Income Tax Ordinance 2023.			
14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:			
Closing market value of marketable securities		12,174,034	17,657,518
Less: Cost of marketable securities		34,928,997	34,928,997
Unrealized gain before adjustment of deferred tax		<u>(22,754,963)</u>	<u>(17,271,479)</u>
Less: Deferred tax on unrealized gain/(loss)		2,275,496	1,727,148
Net unrealized gain/(loss) on marketable securities		<u>(20,479,467)</u>	<u>(15,544,331)</u>
15. RETAINED EARNINGS:			
Opening Balance		3,631,099,007	3,167,771,833
Dividend paid		(199,959,213)	(196,834,850)
Add : Net profit during the period		616,594,530	660,162,024
		<u>4,047,734,323</u>	<u>3,631,099,007</u>
15A. CONSOLIDATED RETAINED EARNINGS:			
Opening Balance		3,625,617,615	3,189,263,114
Dividend paid		(199,959,213)	(196,834,850)
Add: Net profit during the period		624,134,508	633,189,350
		<u>4,049,792,910</u>	<u>3,625,617,615</u>
15B. NON CONTROLLING INTERESTS:			
The IBN SINA API Industry Ltd.		200	200
The IBN SINA Natural Medicine Ltd.		3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)		105,000,000	70,000,000
Add: Share of Profit/(Loss)		(192,860)	943,396
		<u>104,810,340</u>	<u>70,946,596</u>

		Amount in Taka	
		31 March 2026	30 June 2025
16. LONG TERM FINANCE :			
i) From Al-Arafah Islamic Bank PLC Secured (Under Hire Purchase Shirkatul Melk-HPSM)		822,472,601	565,545,640
ii) Pubali Bank PLC (Long Term -H.P.S.M) Pharma		330,816,615	307,123,287
Current maturity transferred to current liability			
From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Mulk)	Note -21	(89,584,391)	(119,445,855)
LONG TERM FINANCE - net off current maturity		1,063,704,824	753,223,072
<p>i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial Position @ 12.50% of profit.</p> <p>ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.</p> <p>iii) HPSM is repayable in 84 monthly equal installment.</p> <p>iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.</p> <p>v) Information regarding loan fall due after five years.</p>			
Loan fall due from 2 to 5 years		548,315,067	377,030,427
Loan fall due from 6 to more years		515,389,757	376,192,645
		1,063,704,824	753,223,072
16.A CONSOLIDATED LONG TERM FINANCE :			
The IBN SINA Pharmaceutical Industry PLC		1,063,704,824	753,223,072
The IBN SINA API Industry Ltd.		222,290,443	221,482,304
		1,285,995,267	974,705,376
17. EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		990,546	1,185,180
Provision during the period		79,005,750	97,491,986
Less: Paid during the period		(77,656,178)	(97,686,620)
		2,340,118	990,546
17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		990,546	1,185,180
Provision during the period		100,872,939	137,250,512
Less: Paid during the period		(99,523,367)	(137,445,146)
		2,340,118	990,546
17. B LEASE LIABILITIES:			
Opening Balance		23,798,698	50,336,979
Finance charge		1,180,678	3,692,459
Paid during the period		(22,385,873)	(30,230,740)
Closing balance		2,593,504	23,798,698
Less : Transferred to current maturity		(2,593,504)	(23,798,698)
		-	-
<p>i) The company has lease against its head office and its training center located at Mohammadpur, Dhaka.</p> <p>ii) Lease period is upto 31.10.2026</p> <p>iii) Monthly rental payment is Tk.1,851,270</p> <p>iv) Advance amount paid Tk. 11,661,000</p> <p>v) Monthly advance adjustment Tk. 50,000</p>			

Amount in Taka

31 March 2026

30 June 2025

18. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax expense/(income) have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,335,558,134	1,815,255,446	520,302,688	20.00%	104,060,538
Gratuity	79,996,297	77,656,178	(2,340,119)	20.00%	(468,024)
Lease	14,469,311	5,481,850	8,987,461	20.00%	1,797,492
Unrealized gain on marketable securities	(22,754,963)	-	(22,754,963)	10.00%	(2,275,496)
As at 31 March 2026	2,407,268,779	1,898,393,474	504,195,068		103,114,510
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,523,691,863	2,054,070,505	464,923,013		94,711,750

DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	103,114,510	94,711,750
Opening balance of deferred tax liability	94,711,750	105,154,476
Total deferred tax expenses/(income)	8,402,759	(10,442,725)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(548,348)	770,401
	7,854,411	(9,672,324)

19 CONSOLIDATED DEFERRED TAX LIABILITY:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,579,097,666	2,050,792,858	528,304,808	20% to 25%	106,126,211
Gratuity	79,996,297	77,656,178	(2,340,119)		(468,024)
Lease	13,435,947	5,481,850	7,954,097	10.00%	1,513,317
Unrealized gain on marketable securities	(22,754,963)	-	(22,754,963)		(2,275,496)
As at 31 March 2026	2,649,774,947	2,133,930,886	511,163,824		104,896,008
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% to 27.50%	99,530,336
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)
Accrued profit on mtdr	-	-	-	-	-
Lease	8,813,099	12,994,333	(4,181,234)	10.00%	(870,815)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,794,797,068	2,318,370,690	471,728,033		96,462,538

CONSOLIDATED DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	104,896,008	96,462,538
Opening balance of deferred tax liability	96,462,538	101,180,186
Total deferred tax expenses/(income)	8,433,469	(4,717,647)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(548,348)	770,401
	7,885,121	(3,947,246)

20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR))	2,179,830,186	933,771,898
	2,179,830,186	933,771,898

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ 15% of profit and 0.25% commission per quarter to be paid.

ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite facilities LC/MPI/MPI TR/UPAS/ Baimuajjal agreement.

iii) Short term loan is repayable with in twelve months.

iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

		Amount in Taka	
		31 March 2026	30 June 2025
20.A CONSOLIDATED SHORT TERM FINANCE :			
A. The IBN SINA Pharmaceutical Industry PLC (Under Composite facilities LC(MPI/TR))		2,179,830,186	933,771,898
B. The IBN SINA API Industry Ltd.		14,816,896	19,911,341
		<u>2,194,647,082</u>	<u>953,683,239</u>
21. CURRENT PORTION OF LONG TERM FINANCE:			
i) From Al-Arafah Islami Bank PLC-Secured (Under Hire Purchase Shirkatul Melk)		<u>89,584,391</u>	<u>119,445,855</u>
The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.			
22. TRADE AND OTHER PAYABLES:			
Payable to suppliers		540,868,807	354,248,263
Provisions	Note-22.1	133,164,239	187,977,710
Accrued expenses		273,891,491	178,532,052
Security money received from employees and others		10,982,585	11,517,972
Workers' profit participation fund & welfare fund		40,083,659	42,953,850
		<u>998,990,781</u>	<u>775,229,847</u>
22.1 PROVISIONS:			
Opening balance		187,977,710	144,607,133
Provisions made during the period		133,164,239	187,977,710
Provisions used during the period		(187,977,710)	(144,607,133)
Closing balance		<u>133,164,239</u>	<u>187,977,710</u>
22.A CONSOLIDATED TRADE AND OTHER PAYABLES :			
Payable to suppliers		578,616,592	396,181,410
Provisions		133,164,239	187,977,710
Accrued expenses		324,411,643	203,253,644
Security money received from employees and others		10,982,585	11,517,972
Workers' profit participation fund & welfare fund		42,631,648	43,358,391
		<u>1,089,806,707</u>	<u>842,289,127</u>
22.B UNCLAIMED DIVIDEND :			
Opening		42,104,508	39,140,597
Addition		199,959,213	196,834,850
Paid to share holders		(208,571,167)	(186,963,608)
Paid to Capital Market Stabilisation Fund		-	(6,907,331)
		<u>33,492,555</u>	<u>42,104,508</u>
22.2 UNCLAIMED DIVIDEND :			
Year-wise break-up of the above is as follows :			
2021-22		-	12,953,290
2022-23		12,886,088	15,606,678
2023-24		12,854,100	13,544,540
2024-25		7,752,367	-
		<u>33,492,555</u>	<u>42,104,508</u>
23. PROVISION FOR CORPORATE TAX:			
Opening balance		458,584,929	255,866,409
Current tax provision		177,224,242	202,718,520
		<u>635,809,171</u>	<u>458,584,929</u>
Adjusted during the year/period		-	-
		<u>635,809,171</u>	<u>458,584,929</u>
23.A CONSOLIDATED PROVISION FOR CORPORATE TAX:			
Opening balance		495,245,930	284,580,559
Current tax expense		192,239,169	210,665,371
		<u>687,485,099</u>	<u>495,245,930</u>
Adjusted during the year/period		-	-
		<u>687,485,099</u>	<u>495,245,930</u>

	Amount in Taka	
	1 July 2025 to 31 March 2026	1 July 2024 to 31 March 2025
24. REVENUE:		
Local revenue	9,147,193,982	7,859,985,361
Export revenue	128,586,312	135,916,946
	9,275,780,294	7,995,902,307
24.A CONSOLIDATED REVENUE:		
The IBN SINA Pharmaceutical Industry PLC	9,275,780,294	7,995,902,307
The IBN SINA Natural Medicine Ltd.	1,129,464,241	817,485,496
	10,405,244,535	8,813,387,803
24.B COST OF GOODS SOLD :		
Materials	4,426,632,444	3,801,299,311
Factory Overhead	997,836,313	888,702,826
Depreciation	101,228,218	103,669,340
	5,525,696,975	4,793,671,477
24.C CONSOLIDATED COST OF GOODS SOLD :		
Materials	4,912,581,401	4,160,481,014
Factory Overhead	1,140,171,028	1,011,171,670
Depreciation	106,102,097	108,778,139
	6,158,854,526	5,280,430,823
25. ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	104,909,692	97,654,318
Repairs & Maintenance	11,388,637	8,833,247
Travelling & Conveyance	5,477,365	3,858,716
AGM, Fees and Others	2,331,213	1,899,390
Depreciation	19,903,030	20,017,222
Other Expenses	38,135,236	41,839,305
	182,145,173	174,102,198
Less: Expenses for INM	-	-
	182,145,173	174,102,198
25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	124,334,388	115,148,592
Repairs & Maintenance	15,009,820	10,279,918
Travelling & Conveyance	5,482,865	3,866,806
AGM, Fees and Others	2,331,213	1,899,390
Research & Development	1,860,118	1,044,499
Depreciation	27,407,096	24,879,034
Other Expenses	53,711,293	48,479,926
	230,136,793	205,598,166
i) Salary, wages & allowance increased due to increase in manpower, gratuity payment.		
ii) Repairs & Maintenance expense increased due to increase in maintenance of fixed assets to meet business needs.		
iii) Travelling & conveyance increased during the period due to increase travel.		
iv) Research & development expense increased during this period due to meet business needs.		
iv) Depreciation expense during the reporting period increased due to addition of fixed assets .		
26. SELLING & DISTRIBUTION EXPENSES :		
Salary, Wages & Allowances	1,688,960,205	1,366,192,807
Travelling & Conveyance	5,768,603	9,044,619
Market Survey & Research and Product development	6,392,783	5,442,691
Field personnel expenses	295,060,409	286,231,107
Sample, Literature & Promotional Expenses	199,427,876	172,488,246
Delivery Expenses	225,641,430	220,203,831
Depreciation	30,347,430	24,104,012
Other Expenses	253,384,546	202,587,846
	2,704,983,281	2,286,295,158
Less: Expenses for INM	(45,178,570)	(32,699,420)
	2,659,804,712	2,253,595,738

	Amount in Taka		
	1 July 2025 to 31 March 2026	1 July 2024 to 31 March 2025	
26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :			
Salary, Wages & Allowances	1,957,244,242	1,574,514,525	
Travelling & Conveyance	9,745,409	10,667,569	
Market Survey & Research and Product development	6,392,783	5,442,691	
Field personnel expenses	368,663,547	342,652,792	
Sample, Literature & Promotional Expenses	230,887,750	212,243,176	
Delivery Expenses	225,641,430	220,203,831	
Depreciation	30,717,616	24,455,223	
Other Expenses	255,118,437	212,402,018	
	<u>3,084,411,213</u>	<u>2,602,581,825</u>	
i) Salary, wages & allowance increase due to increase in manpower, gratuity payment and salary revision.			
ii) Sample, Literature & Promotional Expenses increase in order to increase sales.			
iii) Field personal and delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.			
27. WORKERS' P.P FUND & WELFARE FUND :	<u>40,083,659</u>	<u>34,635,324</u>	
27.A CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :			
The IBN SINA Pharmaceutical Industry PLC	40,083,659	34,635,324	
The IBN SINA Natural Medicine Ltd.	2,547,989	-	
	<u>42,631,648</u>	<u>34,635,324</u>	
28. INCOME TAX EXPENSES:			
Current Tax	177,224,242	155,256,480	
Deferred Tax income/(expense)	7,854,411	15,877,908	
	<u>185,078,653</u>	<u>171,134,388</u>	
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	801,673,183	20.00%	160,334,637
	801,673,183	20.00%	160,334,637
Non Deductible Expenses		2.11%	16,889,605
Deferred Tax (income)/expense		0.98%	7,854,411
		<u>23.09%</u>	<u>185,078,653</u>
28.A CONSOLIDATED INCOME TAX EXPENSES:			
Current Tax	192,239,169	161,131,828	
Deferred Tax income/(expense)	7,885,120	16,098,890	
	<u>200,124,289</u>	<u>177,230,718</u>	
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	823,122,541	20% to 25%	168,615,796
	823,122,541	20.48%	168,615,796
Non Deductible Expenses		2.05%	16,889,605
Deferred Tax (income)/expense		0.95%	7,854,411
		<u>23.49%</u>	<u>193,359,812</u>
29. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :			
Closing value of marketable securities	(22,754,963)	(13,302,777)	
Opening value of marketable securities	(17,271,479)	(9,567,467)	
	<u>(5,483,484)</u>	<u>(3,735,310)</u>	
30. EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)	616,594,530	521,572,088	
Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627	
EARNINGS PER SHARE (EPS)	<u>19.74</u>	<u>16.69</u>	

		Amount in Taka	
		1 July 2025 to 31 March 2026	1 July 2024 to 31 March 2025
30.A CONSOLIDATED EARNINGS PER SHARE (EPS) :			
	Basic earnings per share has been calculated as follows :		
	Earnings attributable to the Ordinary Shareholders (Net profit after tax)	622,998,252	469,366,595
	Divided by number of Ordinary Shares outstanding during the year/period	<u>31,243,627</u>	<u>31,243,627</u>
	CONSOLIDATED EARNINGS PER SHARE (EPS) :	<u><u>19.94</u></u>	<u><u>15.02</u></u>
31. Net Assets Value Per Share (NAV)			
	Equity attributable to the owners of the company	4,344,083,237	3,932,383,056
	Divided by weighed average number of Ordinary Shares outstanding during the period	<u>31,243,627</u>	<u>31,243,627</u>
	Net Assets Value Per Share (NAV)	<u><u>139.04</u></u>	<u><u>125.86</u></u>
	Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.		
31.A Consolidated Net Assets Value Per Share (NAV):			
	Net Assets Value	4,346,141,823	3,926,901,664
	Divided by weighed average number of Ordinary Shares outstanding during the period	<u>31,243,627</u>	<u>31,243,627</u>
	Consolidated Net Assets Value Per Share (NAV):	<u><u>139.10</u></u>	<u><u>125.69</u></u>
32. Net Operating Cash Flow Per Share (NOCFPS):			
	Net cash provided by operating activities	899,620,290	705,019,158
	Divided by weighed average number of Ordinary Shares outstanding during the period	<u>31,243,627</u>	<u>31,243,627</u>
		<u><u>28.79</u></u>	<u><u>22.57</u></u>
32.A Consolidated Net Operating Cash Flows Per Share (NOCFPS):			
	Net cash provided by operating activities	922,437,572	817,362,271
	Divided by weighed average number of Ordinary Shares outstanding during the period	<u>31,243,627</u>	<u>31,243,627</u>
		<u><u>29.52</u></u>	<u><u>26.16</u></u>
33. Reconciliation of net profit with cash flows from operating activities:			
	Profit Before Tax (PBT)	801,673,183	692,706,476
	Adjustment		
	Depreciation	151,478,678	147,790,574
	Deferred Tax	8,402,759	16,251,439
	Unrealized foreign exchange loss	(9,607,793)	(1,039,444)
	Share of associate profit/Loss	-	1,776,249
	Gain on sale of Motor Vehicles	-	-
	Dividend received	-	1,869,684
	Interest Income	(1,669,009)	(400,400)
	Change In operating assets		
	Increase in inventory	(61,332,655)	(137,881,076)
	Increase in accounts receivables	(71,863,603)	(30,675,350)
	Decrease in advances, deposits and prepayments	35,937,109	9,112,374
	Increase/(decrease) in trade and other payable	248,159,783	177,282,262
	Increase/(decrease) in retirement benefit obligation	1,349,572	356,813
	Finance charge	(89,008,419)	(56,685,494)
	Tax paid during the period	<u>(113,899,225)</u>	<u>(115,444,950)</u>
		<u><u>899,620,380</u></u>	<u><u>705,019,158</u></u>
34. Finance Charge:			
	Finance charge for long term finance	89,008,419	56,685,494
	Finance charge for lease	<u>1,180,678</u>	<u>2,987,876</u>
		<u><u>90,189,097</u></u>	<u><u>59,673,370</u></u>
34.A Consolidated Finance Charge:			
	Finance charge for long term finance	89,008,419	56,685,494
	Finance charge for lease	<u>1,180,678</u>	<u>2,987,876</u>
		<u><u>90,189,097</u></u>	<u><u>59,673,370</u></u>


35. RELATED PARTY DISCLOSURE:

Name of party	Relationship	Nature of transaction	Transaction		March 2026	June 2025
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		80,000,000	749,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Administrative Expenses Distribution Expense	- 45,178,570	-	238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital	-	65,000,000	195,000,000	130,000,000


35.01. NON-CONTROLLING INTEREST


The IBN SINA API Industry Ltd.
The IBN SINA Natural Medicine Ltd.
The IBN SINA Polymer Industry Ltd.

Profit Amount	NCI (%)	Net Amount
(26,954,358)	0.000050	(13)
36,033,336	0.001260	454
(3,247,703)	35.000000	(1,136,696)
5,831,275		(1,136,256)


Chief Financial Officer


Company Secretary


Director, Finance


Dated, Dhaka .
22 April 2026


Managing Director


Chairman